Literature DB >> 7723729

Regulation of the constitutive expression of the human CYP1A2 gene: cis elements and their interactions with proteins.

I Chung1, E Bresnick.   

Abstract

Cytochrome P4501A2 (CYP1A2) is a member of the cytochrome P450 family that is involved in phase I drug metabolism in vertebrates. To understand how the constitutive expression of the human CYP1A2 gene is regulated, its 5' flanking region was analyzed. The promoter activity of a human CYP1A2 gene sequence [base pairs (bp) -3203 to +58 bp] was measured in transiently transfected HepG2 cells using fusion constructs containing the luciferase reporter gene. Using 5'-end deletion analysis, two functionally important cis elements, i.e., a proximal 42-bp DNA from bp -72 to bp -31 and a distal 259-bp DNA from bp -2352 to bp -2094, were identified. The proximal sequence (bp -72 to -31) contained CCAAT and GC boxes, with which well characterized transcription factors such as nuclear factor-1/CCAT transcription factor and simian virus 40 promoter factor-1 could interact. With regard to the 259-bp fragment (bp -2352 to bp -2094), gel mobility shift analyses with HepG2 nuclear lysates indicated high affinity, specific interactions of several trans-acting factors. Three protein binding sites within the 259-bp fragment were identified by DNase 1 footprinting analysis; these sites contained activator protein-1, nuclear factor-E1.7, and one-half hepatic nuclear factor-1 (HNF-1) binding consensus sequences. Only the region from bp -2124 to bp -2098, in which the HNF-1 binding site was located, was markedly protected by a HepG2 nuclear extract, compared with a MCF7 human breast cancer nuclear extract. These results suggested that the 259-bp DNA fragment contained positive regulator binding sites and HNF-1 could contribute to the liver-specific expression of human CYP1A2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7723729

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

Review 1.  Role of beta-catenin in the adult liver.

Authors:  Frank J Gonzalez
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

2.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

3.  The gut-enriched Krüppel-like factor suppresses the activity of the CYP1A1 promoter in an Sp1-dependent fashion.

Authors:  W Zhang; J M Shields; K Sogawa; Y Fujii-Kuriyama; V W Yang
Journal:  J Biol Chem       Date:  1998-07-10       Impact factor: 5.157

4.  Adaptively inferring human transcriptional subnetworks.

Authors:  Debopriya Das; Zaher Nahlé; Michael Q Zhang
Journal:  Mol Syst Biol       Date:  2006-06-06       Impact factor: 11.429

5.  Baicalin Protects Mice from Aristolochic Acid I-Induced Kidney Injury by Induction of CYP1A through the Aromatic Hydrocarbon Receptor.

Authors:  Ke Wang; Chenchen Feng; Chenggang Li; Jun Yao; Xiaofeng Xie; Likun Gong; Yang Luan; Guozhen Xing; Xue Zhu; Xinming Qi; Jin Ren
Journal:  Int J Mol Sci       Date:  2015-07-20       Impact factor: 5.923

Review 6.  Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.

Authors:  Laura M de Jong; Wim Jiskoot; Jesse J Swen; Martijn L Manson
Journal:  Genes (Basel)       Date:  2020-12-16       Impact factor: 4.096

Review 7.  The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.

Authors:  Kuo-Chen Wu; Chun-Jung Lin
Journal:  J Food Drug Anal       Date:  2018-12-04       Impact factor: 6.157

8.  CYP1A2 polymorphism and theophylline clearance in Korean non-smoking asthmatics.

Authors:  Eun-Young Yim; Hye-Ryun Kang; Jae-Woo Jung; Seong-Wook Sohn; Sang-Heon Cho
Journal:  Asia Pac Allergy       Date:  2013-10-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.